Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease

Inclusion Criteria: * Written informed consent obtained from the subject prior to performing any protocol- related procedures, including screening procedures * Histological or cytological diagnosis of NSCLC * Stage IV disease with ≤5 metastases (not including primary tumour or mediastinal nodes, N1-N3) * Patient deemed fit for first line chemoimmunotherapy, immunotherapy or chemotherapy * Extra-thoracic metastases accessible for stereotactic body radiotherapy (SBRT) * Thoracic tumour(s) accessible for SBRT or conventional radiotherapy * Received no prior systemic treatment or radiation therapy for NSCLC (previous adjuvant systemic therapy is allowed) * Age \> 18 years at time of study entry, no upper age limit * WHO performance status 0-2 * Adequate normal organ and marrow function Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects. * Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up Exclusion Criteria: * • Solitary brain lesion or contralateral lung lesion as the only distant metastasis * Participation in another clinical study with an investigational product during the last 4 weeks * Patients with EGFR+, ALK+, ROS1+ disease or any other genetic alteration that would result in a TKI based first line treatment (i.e. first line treatment not being chemoimmuno- …